Dark

OCUL
Ocular Therapeutix, Inc.
stock NASDAQ

At Close

Dec 26, 2025 3:59:55 PM EST

12.58USD-1.023%(-0.13)1,151,580

0.00Bid 0.00Ask 0.00Spread

Pre-market

Dec 24, 2025 9:27:30 AM EST

12.70USD-0.079%(-0.01)0

After-hours

Dec 26, 2025 4:00:30 PM EST

12.56USD-0.159%(-0.02)15,113

OverviewOptionsHistoricalExchangesShortsNews

Jan 18, 2022

08:07AM EST Ocular Therapeutix Announces AffaMed Therapeutics, licensee Of DEXTENZA In Certain Asian Markets, Doses Their First Patient In Clinical Trial Evaluating The Safety And Efficacy Of DEXTENZA In China In Cataract Surgery Patients Benzinga

Dec 15, 2021

05:18AM EST Ocular Therapeutix 10%+ Owner Summer Road LLC Reported Purchase of 40,510 Shares @ Avg Price of $6.61/Share in Form 4 Filing on Tuesday Benzinga

Dec 6, 2021

07:03AM EST Ocular Therapeutix Announces Topline Results For Phase 2 Clinical Trial Of OTX-DED For The Short-Term Treatment Of Dry Eye Disease' Co. Reports 'Study shows statistically significant improvement for primary endpoint' Benzinga

Nov 9, 2021

01:26PM EST Expert Ratings For Ocular Therapeutix Benzinga

11:51AM EST Ocular Therapeutix Announces Success In Patent Appeal Brought By Mati Therapeutics Benzinga

11:44AM EST JMP Securities Maintains Market Outperform on Ocular Therapeutix, Raises Price Target to $30 Benzinga

11:17AM EST Ocular Therapeutix: Q3 Earnings Insights Benzinga

11:05AM EST Ocular Therapeutix Q3 Sales $12.15M Miss $12.45M Estimate Benzinga

Nov 8, 2021

05:06AM EST Earnings Scheduled For November 8, 2021 Benzinga

Nov 5, 2021

09:44AM EDT Ocular Therapeutix Announces Update From Centers For Medicare And Medicaid Services For Reimbursement Of DEXTENZA Benzinga

Oct 25, 2021

02:57PM EDT What 5 Analyst Ratings Have To Say About Ocular Therapeutix Benzinga

07:24AM EDT 10 Biggest Price Target Changes For Monday Benzinga

06:25AM EDT HC Wainwright & Co. Maintains Buy on Ocular Therapeutix, Lowers Price Target to $14 Benzinga

Oct 22, 2021

04:10PM EDT Mid-Afternoon Market Update: Nasdaq Down 70 Points; Ocular Therapeutix Shares Drop Benzinga

12:49PM EDT Mid-Day Market Update: Snap Drops After Q3 Results; Creatd Shares Jump Benzinga

10:08AM EDT Mid-Morning Market Update: Markets Mixed; American Express Earnings Beat Views Benzinga

08:09AM EDT Ocular Therapeutix Shares Were Halted Ahead Of Recent News; Stock To Resume Trade At 8:30 a.m. EDT Benzinga

08:02AM EDT Ocular Therapeutix Announces Topline Results For Phase 2 Clinical Trial Of OTX-CSI For The Treatment Of Dry Eye Disease Did Not Meet Primary Endpoint Benzinga

Oct 18, 2021

08:26AM EDT 10 Biggest Price Target Changes For Monday Benzinga

07:34AM EDT The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs Benzinga

04:56AM EDT Raymond James Maintains Strong Buy on Ocular Therapeutix, Raises Price Target to $29 Benzinga

Oct 12, 2021

07:01AM EDT HC Wainwright & Co. Maintains Buy on Ocular Therapeutix, Raises Price Target to $18 Benzinga

Oct 1, 2021

02:29PM EDT Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates Benzinga

Sep 21, 2021

01:05PM EDT Ocular Therapeutix Option Alert: Nov 19 $12 Calls Sweep (20) near the Ask: 396 @ $0.928 vs 22 OI; Earnings 11/4 After Close [est] Ref=$10.18 Benzinga

Sep 13, 2021

06:48AM EDT Ocular Therapeutix Reports Monthly In-Market Unit Sales Of DEXTENZA Billable Inserts Of 6,924 In July And 9,321 In August Benzinga

Sep 9, 2021

08:16AM EDT JMP Securities Maintains Market Outperform on Ocular Therapeutix, Raises Price Target to $33 Benzinga

Aug 10, 2021

10:32AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2021 Benzinga

06:27AM EDT HC Wainwright & Co. Upgrades Ocular Therapeutix to Buy, Announces $17 Price Target Benzinga

Aug 9, 2021

04:46PM EDT Ocular Therapeutix Filing Shows Registration For $100M Common Stock Offering Benzinga

04:23PM EDT Ocular Therapeutix Q2 EPS $(0.25) Misses $(0.21) Estimate, Sales $11.72M Beat $11.60M Estimate Benzinga

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

04:11AM EDT Earnings Scheduled For August 9, 2021 Benzinga

Aug 8, 2021

10:11AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 6, 2021

10:09AM EDT Ocular Therapeutix, Regeneron Cull Aflibercept Agreement For Retinal Diseases Benzinga

07:42AM EDT The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO Benzinga

Aug 5, 2021

04:26PM EDT Ocular Therapeutix Announces Termination Of Collaboration With Regeneron To Develop A Sustained-Release Formulation Of Aflibercept For The Treatment Of Wet AMD And Other Serious Retinal Diseases Benzinga

Aug 4, 2021

08:43AM EDT Ocular Therapeutix Sponsored Study Titled 'Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration' Posted To ClinicalTrials.Gov Site Benzinga

Jul 29, 2021

08:08AM EDT Ocular Therapeutix Announces First Patient Dosed In US-Based Phase 1 Clinical Trial Of OTX-TKI For Treatment Of Wet Age-Related Macular Degeneration Benzinga

Jul 23, 2021

08:10AM EDT Ocular Therapeutix Will Present Clinical Data At American Society of Cataract and Refractive Surgery Annual Meeting Jul. 23-27, 2021 Benzinga

07:45AM EDT The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs Benzinga

Jul 22, 2021

04:10PM EDT Ocular Therapeutic Reports Q2 Prelim. Product Sales Of $11.7M, Up 600% YoY Benzinga

Jun 30, 2021

12:24PM EDT Ocular Therapeutics Publishes Study Titled 'A Human Factors Study to Evaluate a Novel Intracanalicular Insertion Device in Healthy Subjects' To ClinicalTrials.Gov Website Benzinga

Jun 29, 2021

08:04AM EDT Ocular Therapeutix Reports Strategic Discovery Collaboration With Mosaic Biosciences For Treatment Of Dry Age-Related Macular Degeneration, No Terms Disclosed Benzinga

May 24, 2021

10:58AM EDT Ocular Therapeutix Option Alert: Sep 17 $17 Calls Sweep (32) near the Ask: 510 @ $2.146 vs 20 OI; Ref=$13.63 Benzinga

May 5, 2021

04:15PM EDT Ocular Therapeutix Q1 EPS $(0.24) Misses $(0.21) Estimate, Sales $7.34M Miss $7.64M Estimate Benzinga

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

04:16AM EDT Earnings Scheduled For May 5, 2021 Benzinga

May 3, 2021

08:27AM EDT Ocular Therapeutix Fulfills Post-Marketing Approval Requirements for ReSure Sealant Benzinga

Mar 12, 2021

11:00AM EST Ocular Therapeutix shares were trading lower after the company reported Q4 EPS of $(1.21), down from $(0.54) year over year and worse-than-expected Q4 sales results. Benzinga

Mar 11, 2021

04:02PM EST Ocular Therapeutix Q4 EPS $(1.21) Down From $(0.54) YoY, Sales $7.35M Miss $9.76M Estimate Benzinga

08:19AM EST The Daily Biotech Pulse: Contrasting COVID-19 Treatment Readouts From Roche, Vir, Delay In Kadmon's FDA Review, Alzheimer's Data From Prothena Benzinga

03:35AM EST Earnings Scheduled For March 11, 2021 Benzinga

Mar 10, 2021

10:04AM EST Preview: Ocular Therapeutix's Earnings Benzinga

Mar 6, 2021

10:58AM EST The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings Benzinga

Mar 5, 2021

10:49AM EST Ocular Therapeutics shares were trading higher after the company announced the supplemental New Drug Application for DEXTENZA 0.4 mg for intracanalicular use has been accepted for review by the FDA. Benzinga

Mar 4, 2021

04:04PM EST UPDATE: Ocular Therapeutix Reports PDUFA Action Date Oct. 18, 2021 Benzinga

04:03PM EST Ocular Therapeutix Reports FDA Acceptance Of Supplemental New Drug Application For DEXTENZA For Treatment Of Ocular Itching Associated With Allergic Conjunctivitis Benzinga

Mar 1, 2021

01:03PM EST Ocular Therapeutix Shares Are Trading Higher As Company Starts Dosing In Mid-Stage Therapy Study For Dry Eye Disease Benzinga

07:10AM EST Ocular Therapeutix Announces First Patient Dosed in Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease Benzinga

Feb 16, 2021

05:43AM EST Ocular Therapeutix's Intravitreal Implant Shows Decrease In Retinal Fluid In Early-Stage Wet AMD Study Benzinga

Jan 20, 2021

08:03AM EST Ocular Therapeutix Highlights Presentation Of Interim Topline Data From Phase 1 Clinical Trial Of OTX-TIC In Patients With Primary Open Angle Glaucoma Or Ocular Hypertension At 10th Annual Glaucoma 360 New Horizons Forum Benzinga

Dec 28, 2020

06:38AM EST HC Wainwright & Co. Downgrades Ocular Therapeutix to Neutral Benzinga

Dec 22, 2020

08:47AM EST Ocular Therapeutix Announces Submission Of Supplemental New Drug Application For DEXTENZA To FDA For Treatment of Ocular Itching Associated With Allergic Conjunctivitis Benzinga

Dec 17, 2020

10:17AM EST Benzinga's Top Upgrades, Downgrades For December 17, 2020 Benzinga

09:57AM EST Berenberg Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces Price Target of $27 Benzinga

08:10AM EST The Daily Biotech Pulse: MacroGenics Breast Cancer Drug Wins FDA Approval, Adcom Test Awaits Moderna, Virios To Make Wall Street Debut Benzinga

Dec 16, 2020

07:15AM EST The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal Benzinga

Dec 15, 2020

07:52AM EST The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding Benzinga

Dec 14, 2020

04:13PM EST Ocular Therapeutix Reports $75M Common Stock Offering Benzinga

04:09PM EST Ocular Therapeutix Filing Shows Registration For Mixed Securities Offering, No Size Disclosed Benzinga

Dec 11, 2020

08:11AM EST The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street Benzinga

Dec 8, 2020

08:04AM EST The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings Benzinga

Dec 4, 2020

08:04AM EST The Daily Biotech Pulse: BioCryst's Heredity Angioedema Treatment Clears FDA, Sutro Biopharma Readout, 2 IPOs Benzinga

Dec 1, 2020

08:08AM EST The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit Benzinga

Nov 25, 2020

07:35AM EST The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback Benzinga

Nov 24, 2020

08:13AM EST The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia Benzinga

Nov 17, 2020

08:32AM EST The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration Benzinga

Nov 16, 2020

10:02AM EST 68 Stocks Trading Near 52-Week Highs Just After Open On Monday, Nov. 16, 2020: Benzinga

Nov 13, 2020

01:27PM EST Ocular Therapeutics Tick Higher; Hearing Price Target Raised From $15 To $25 At Raymond James Benzinga

07:40AM EST The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations Benzinga

Nov 11, 2020

09:03AM EST Ocular Therapeutix To Present Data At The American Academy Of Ophthalmology 2020 Virtual Annual Meeting Benzinga

07:38AM EST The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap Benzinga

Nov 10, 2020

08:40AM EST The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies Benzinga

Nov 6, 2020

09:50AM EST Ocular Therapeutix shares are trading lower after the company reported Q3 earnings results. Benzinga

06:34AM EST HC Wainwright & Co. Maintains Buy on Ocular Therapeutix, Raises Price Target to $14 Benzinga

Nov 5, 2020

04:15PM EST Ocular Therapeutix Q3 EPS $(0.21) Beats $(0.24) Estimate, Sales $5.90M Beat $5.49M Estimate Benzinga

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 4, 2020

08:01AM EST Ocular Therapeutix Reports Receipt Of Permanent Category I CPT Code From American Medical Association For Insertion Of Intracanalicular Inserts Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 30, 2020

08:04AM EDT UPDATE: Ocular Therapeutix To Receive $12M Upfront Fee And Development And Commercialization Milestones And Other Payments Of Up To $91M Plus Additional Royalties On Future Product Sales Benzinga

08:03AM EDT Ocular Therapeutix and AffaMed Therapeutics Announce License Agreement and Collaboration for DEXTENZA and OTX-TIC in Asia Benzinga

Oct 15, 2020

04:30PM EDT 10 Stocks Moving In Tuesday's After-Hours Session Benzinga

Oct 14, 2020

06:32AM EDT Ocular Therapeutix Prices 7.18M Share Common Stock Offering At $9.75/Share Benzinga

Oct 13, 2020

05:21PM EDT 10 Stocks Moving In Tuesday's After-Hours Session Benzinga

05:03PM EDT Ocular Therapeutix Announces Proposed Public Offering of Common Stock; No Terms Disclosed Benzinga

Oct 8, 2020

08:09AM EDT Ocular Therapeutix Announces Topline Phase 1 Clinical Trial Results of OTX-CSI; Reports 'OTX-CSI demonstrates improvement in signs and symptoms of Dry Eye Disease' Benzinga

Oct 7, 2020

10:59AM EDT Why Ocular Therapeutix's Stock Is Trading Higher Today Benzinga

10:18AM EDT Shares of Ocular Therapeutix, Inc. (OCUL) are climbing more than 17% Wednesday morning after the company announced that its third-quarter preliminary product revenue represents 250% sequential increase. RTTNews

08:09AM EDT Ocular Therapeutix Sees Prelim. Q3 Net Product Sales $5.8M-$5.9M Benzinga

Sep 29, 2020

08:07AM EDT Ocular Therapeutix Announces First Patients Dosed in Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease Benzinga

Sep 10, 2020

07:13AM EDT Ocular Therapeutics Announces The Dosing Of The First Patient In Its Phase 3 Clinical Trial Of DEXTENZA For The Treatment Of Post-Surgical Ocular Inflammation And Pain In Children Benzinga

Sep 8, 2020

07:01AM EDT Ocular Therapeutix Announces Successful Resolution Of FDA Warning Letter Related To ReSure Sealant Benzinga

Sep 4, 2020

07:01AM EDT Ocular Therapeutix Announces National Government Services Became The Third Medicare Administrative Contractor to Establish New Published Physician Fee Schedule for Administration of Intracanalicular Inserts Benzinga

Aug 7, 2020

07:34AM EDT Ocular Therapeutix: Q2 Earnings Insights Benzinga

07:30AM EDT Ocular Therapeutix Q2 EPS $(0.64) Misses $(0.31) Estimate, Sales $1.57M Beat $1.50M Estimate Benzinga

04:02AM EDT Earnings Scheduled For August 7, 2020 Benzinga

Aug 6, 2020

04:08PM EDT Earnings Outlook for Ocular Therapeutix Benzinga

Jul 17, 2020

07:39AM EDT Ocular Therapeutix Projects Total Product Net Revenue Of $1.6 Million For June Quarter RTTNews

07:30AM EDT Ocular Therapeutix Presents at the 12th Annual Ophthalmology Innovation Summit (OIS) Business Wire